National and Kapodistrian University of Athens
Μέτρηση του αιμοπεταλιακού ενδοθηλιακού παράγοντα (PD6F) ανδρών στο καρκίνο του προστάτη
Abstract
dc:descriptionProstate adenocarcinoma is the most common cancer in men (approximately 11.7% of new cases of prostate cancer are diagnosed annually worldwide) and is the second most common cause of cancer death. It is estimated that about 40% of men over the age of 50 have prostate cancer prostates without symptomatic or metastatic disease. A large increase in incidence rates of PCA has been observed in many countries worldwide, combined with a small decrease in mortality rates. Most of this increase can be attributed to the widespread use of PSA in Western countries, which can detect both invasive cancers and non-lethal latent patients who, without the use of PSA, would remain asymptomatic and undiagnosed over the course of their lives of the patient. However, PSA, although the best biomarker available for PCA, is a marker specific to the prostate but not for a disease, often creating diagnostic dilemmas. The search for new biomarkers for prostate cancer is imperative. Based on a previous proteomic study of of the A University Urology Clinic of Athens performed on prostate tissue and based on bibliographic data, a protein was selected to be studied in the urine of the participants. 118 urine specimens of high-risk individuals were collected for Pca based on either the dascal or elevated PSA or the abnormal change in PSA time. The PDGF protein studied had a sensitivity of 63.6% and a specificity of 55.7%. The resolution of PDGFbb / Cr in patients with PSA levels of 4-10 ng / ml did not reach statistically significant (p = 0.065). The ROC curve analysis showed that the optimal cleavage of PDGFbb to predict prostate cancer was 1504.9 with a sensitivity of 60% and a specificity of 51.3%. In addition, ROC analysis showed a cut of 1217.7 for PDGFbb / Cr with a sensitivity of 67.5% and a specificity of 52.6%. Separate analysis in patients with PSA levels of 4-10 ng / ml showed that PDGFbb had a resolution with an AUC of 0.65. The optimal cut was 1534.5 for PDGFbb with a sensitivity of 63.6% and a specificity of 55.7%. The resolution of 153 PDGFbb / Cr in patients with PSA levels of 4-10 ng / ml did not reach statistically significant (p = 0.065). PDGFbb displayed significant predictive capacity for Pca as a self-evident biomarker. Additionally, the addition of PDGFbb to PSA significantly improved the PSA's predictive value, which is also important as PSA is still the major biomarker for PCA, and any biomarker that improves performance improves our ability to diagnose cancer early of the prostate.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Skarmoutsos, Athanasios
- Σκαρμούτσος, Αθανάσιος
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45189